Sanofi-Aventis Taps Avila Technology | January 10, 2011 Issue - Vol. 89 Issue 2 | Chemical & Engineering News
Volume 89 Issue 2 | p. 19 | Concentrates
Issue Date: January 10, 2011

Sanofi-Aventis Taps Avila Technology

Department: Business
Keywords: Avila, Sanofi, covalent drugs

Sanofi-Aventis and Avila Therapeutics will work jointly to discover cancer treatments through Avila’s covalent drug technology, which enables compounds to form permanent bonds with their target proteins. Under the deal, the companies will develop covalent drugs targeting six signaling proteins active in tumor cells. Avila scores $40 million up front and research support. It could earn up to $154 million per compound in milestone payments. The Waltham, Mass.-based biotech firm also gets to keep the rights to one of the molecules at the end of the three-year pact.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment